Preferences for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.
NCT ID: NCT05936632
Last Updated: 2024-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
998 participants
OBSERVATIONAL
2023-07-07
2023-07-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It is not currently known if (and under which circumstances) people would prefer to wait to access some new drugs in exchange for greater certainty surrounding their clinical benefit.
This study aims to elicit the preferences of people in the US with experience of cancer for wait times and clinical uncertainty of new drugs.
To elicit this information, in a survey format, respondents will be presented with a hypothetical scenario and asked to state their preferences for new treatments, each with different attributes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Communicating Multiple Uncertainties Associated With the Benefits and Risks of New Cancer Drugs
NCT07110597
Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs
NCT06997185
Evaluating Patient Participation in Phase I Clinical Trials
NCT00043030
Study of Decision Making in Patients Participating in Phase I Clinical Trials
NCT00054223
Perspective-taking, and Examining the Clinical Trial Informed Consent Process
NCT01778582
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Discrete Choice Experiment (DCE)
DCE survey experiment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals with immediate family members previously or currently diagnosed with any type of cancer.
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
London School of Economics and Political Science
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Robin Forrest
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
London School of Economics
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Forrest R, Lagarde M, Aggarwal A, Naci H. Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. Lancet Oncol. 2024 Dec;25(12):1635-1643. doi: 10.1016/S1470-2045(24)00596-5. Epub 2024 Nov 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
213621
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.